Drug Trial Radar · NCT05283226
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
Last checked: Nov 20, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
21
Planned (sponsor's estimate)
Start
Sep 30, 2022
Primary completion
Dec 30, 2026
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- NATCO Pharma Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, open-label, multicenter, single-arm study of NRC-2694-A in combination with paclitaxel in patients with R/M HNSCC with progression on or after ICI therapy. A total of approximately 46 male and female patients will be enrolled. This sample size is based on Simon's 2-stage design with historical control ORR of 30% and a target ORR of 50%.
Conditions
- Carcinoma
- Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Interventions
NRC-2694-ADrug
300 mg orally once daily
PaclitaxelDrug
175 mg/m² IV infusion over approximately 3 hours
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine if NRC-2694-A administered orally in combination with paclitaxel demonstrates objective response in patients with R/M HNSCC, who have had radiological progression on or after treatment with ICI therapies like pembrolizumab or nivolumabTime frame: Baseline through approximately up to 24 weeks
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
Providence Medical Foundation -Fullerton
Fullerton, California · Completed
Los Angeles Hematology Oncology Medical Group
Los Angeles, California · Completed
Lynn Cancer Center
Boca Raton, Florida · Completed
Miami Cancer Center
Miami, Florida · Completed
Norton Cancer Institute - Downtown
Louisville, Kentucky · Completed
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland · Completed
Washington University - Siteman Cancer Center
St Louis, Missouri · Completed
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire · Completed
Salib Oncology
Easton, Pennsylvania · Completed
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin · Completed
Daycare Angels under AOH
Mumbai, Maharashtra, India · Recruiting
Grant Medical Foundation Ruby Hall Clinic
Pune, Maharashtra, India · Completed
Basavatarakam Indo American Cancer Hospital & Research Institute
Hyderabad, Telangana, India · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.